| Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer M Reck, D Rodríguez-Abreu, AG Robinson, R Hui, T Csőszi, A Fülöp, ... New England Journal of Medicine 375 (19), 1823-1833, 2016 | 9501 | 2016 |
| Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non–small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater M Reck, D Rodríguez–Abreu, AG Robinson, R Hui, T Csőszi, A Fülöp, ... Journal of clinical oncology 37 (7), 537-546, 2019 | 1404 | 2019 |
| Increased oxidative stress in patients with congestive heart failure M Keith, A Geranmayegan, MJ Sole, R Kurian, A Robinson, AS Omran, ... Journal of the American College of Cardiology 31 (6), 1352-1356, 1998 | 768 | 1998 |
| Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non–small-cell lung cancer with PD-L1 tumor proportion score≥ 50% M Reck, D Rodríguez-Abreu, AG Robinson, R Hui, T Csőszi, A Fülöp, ... Journal of Clinical Oncology 39 (21), 2339, 2021 | 640 | 2021 |
| A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol-specified final analysis of KEYNOTE-407 L Paz-Ares, D Vicente, A Tafreshi, A Robinson, HS Parra, J Mazières, ... Journal of Thoracic Oncology 15 (10), 1657-1669, 2020 | 534 | 2020 |
| Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open … JR Brahmer, D Rodríguez-Abreu, AG Robinson, R Hui, T Csőszi, A Fülöp, ... The Lancet Oncology 18 (12), 1600-1609, 2017 | 345 | 2017 |
| Therapy for stage IV non–small-cell lung cancer without driver alterations: ASCO and OH (CCO) joint guideline update NH Hanna, BJ Schneider, S Temin, S Baker Jr, J Brahmer, PM Ellis, ... Journal of Clinical Oncology, 2020 | 293 | 2020 |
| Therapy for stage IV non–small-cell lung cancer with driver alterations: ASCO and OH (CCO) joint guideline update NH Hanna, AG Robinson, S Temin, S Baker Jr, JR Brahmer, PM Ellis, ... Journal of Clinical Oncology 39 (9), 1040-1091, 2021 | 257 | 2021 |
| Pembrolizumab exposure–response assessments challenged by association of cancer cachexia and catabolic clearance DC Turner, AG Kondic, KM Anderson, AG Robinson, EB Garon, JW Riess, ... Clinical Cancer Research 24 (23), 5841-5849, 2018 | 176 | 2018 |
| Pembrolizumab plus chemotherapy in squamous non–small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study S Novello, DM Kowalski, A Luft, M Gümüş, D Vicente, J Mazières, ... Journal of Clinical Oncology 41 (11), 1999, 2023 | 143 | 2023 |
| STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer A Ghaffari, N Peterson, K Khalaj, N Vitkin, A Robinson, JA Francis, M Koti British journal of cancer 119 (4), 440-449, 2018 | 139 | 2018 |
| Therapy for stage IV non–small-cell lung cancer without driver alterations: ASCO living guideline N Singh, S Temin, S Baker Jr, E Blanchard, JR Brahmer, P Celano, ... Journal of Clinical Oncology 40 (28), 3323-3343, 2022 | 121 | 2022 |
| LBA51 KEYNOTE-024 5-year OS update: First-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour … JR Brahmer, D Rodriguez-Abreu, AG Robinson, R Hui, T Csőszi, A Fülöp, ... Annals of Oncology 31, S1181-S1182, 2020 | 121 | 2020 |
| Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American … CB Moeder, JM Giltnane, M Harigopal, A Molinaro, A Robinson, ... Journal of Clinical Oncology 25 (34), 5418-5425, 2007 | 121 | 2007 |
| OA 17.06 updated analysis of KEYNOTE-024: pembrolizumab vs platinum-based chemotherapy for advanced NSCLC with PD-L1 TPS≥ 50% J Brahmer, D Rodríguez-Abreu, A Robinson, R Hui, T Csőszi, A Fülöp, ... Journal of Thoracic Oncology 12 (11), S1793-S1794, 2017 | 93 | 2017 |
| RBM5 as a putative tumor suppressor gene for lung cancer LC Sutherland, K Wang, AG Robinson Journal of Thoracic Oncology 5 (3), 294-298, 2010 | 91 | 2010 |
| Metformin in combination with chemoradiotherapy in locally advanced non–small cell lung cancer: The OCOG-ALMERA randomized clinical trial T Tsakiridis, GR Pond, J Wright, PM Ellis, N Ahmed, B Abdulkarim, W Roa, ... JAMA oncology 7 (9), 1333-1341, 2021 | 79 | 2021 |
| Progression after the next line of therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS)≥ 50% enrolled in KEYNOTE-024. JR Brahmer, D Rodriguez-Abreu, AG Robinson, R Hui, T Csõszi, A Fülöp, ... Journal of Clinical Oncology 35 (15_suppl), 9000-9000, 2017 | 74 | 2017 |
| A randomised trial of 4-versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer M Clemons, M Ong, C Stober, S Ernst, C Booth, C Canil, M Mates, ... European Journal of Cancer 142, 132-140, 2021 | 55 | 2021 |
| Molecular predictive factors in patients receiving trastuzumab-based chemotherapy for metastatic disease AG Robinson, D Turbin, T Thomson, E Yorida, S Ellard, C Bajdik, ... Clinical breast cancer 7 (3), 254-261, 2006 | 52 | 2006 |
